Myelofibrosis with myeloid metaplasia in a patient with relapsed Hodgkin's lymphoma who underwent autologous hematopoietic stem cell transplantation

Hematology

Volumn 12, Issue 6, 2007, Pages 487-488

  Massa, Federico Sackmann ^a   Rolón, Juliana Martinez ^a   Pavlovsky, Santiago ^a  

^a Fundacion para Combatir La Leucemia   (Argentina)

Author keywords

Autologous hematopoietic stem cell transplantation; Hodgkin's lymphoma; Myelofibrosis with myeloid metaplasia; Second neoplasms

Indexed keywords

AMPHOTERICIN; ANTIBIOTIC AGENT; CARMUSTINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; JANUS KINASE 2; MESNA; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADULT; ANEMIA; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD TRANSFUSION; CANCER RELAPSE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CYTOGENETICS; FEBRILE NEUTROPENIA; FOLLOW UP; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; MALE; MULTIPLE CYCLE TREATMENT; MYELOFIBROSIS; MYELOID METAPLASIA; PNEUMOCYSTOSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SPLENOMEGALY; STOMATITIS;

ADULT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; MALE; MYELOFIBROSIS; MYELOID METAPLASIA; NEOPLASMS, SECOND PRIMARY; RECURRENCE; TRANSPLANTATION, AUTOLOGOUS;

EID: 35748967887     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1080/10245330701631272     Document Type: Article

References (8)

1. Murphy, F., Sirohi, B. and Cunningham, D. (2007) Stem cell transplantation in Hodgkin lymphoma. Expert Rev Anticancer Ther, 7, pp. 297-306.
2. Deeg, J. and Socié, G. (1998) Malignancies after hematopoietic stem cell transplantation: Many questions, some answers. Blood, 91, pp. 1833-1844.
3. Dores, GM, Metayer, C., Curtis, RE, Lynch, C., Clarke, A., Glimelius, B. and Storm, H. (2002) Second malignant neoplasms among long-term survivors of Hodgkin's disease: A population based evaluation over 25 years. J Clin Oncol, 20, pp. 3484-3494.
4. Forrest, D., Hogge, D., Nevill, T., Nantel, S., Barnett, M. and Shepherd, J. (2005) High dose therapy and autologous hematopoietic stem cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: A comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem cell transplantation. J Clin Oncol, 23, pp. 7994-8002.
5. Adés, L., Guardiola, P. and Socié, G. (2002) Second malignancies after allogeneic hematopoietic stem cell transplantation: New insight and current problems. Blood Rev, 16, pp. 135-146.
6. Forrest, DL, Nevill, TJ, Naiman, SC, Brockington, DA and Barnett, MJ (2003) Second malignancy following high-dose theraphy and autologous stem cell transplantation: Incidence and risk factor analysis. Bone Marrow Transplant, 32, pp. 915-923.
7. Walker, AR, Rothberg, PG and Liesveld, JL (2007) A case of JAK2 positive essential trombocitemia 16.5 years after autologous marrow transplantation for AML. Bone Marrow Transplant
8. Vukelja, SJ, Krinshnan, J., Ward, FT and Redmond III, J. (1990) Synchronous Hodgkin's disease and myelofibrosis terminating with granulocytic sarcoma and acute megakaryocytic leukaemia. South Med, 83, pp. 1317-1320.